新藥股DNA解密

為了讓投資人更了解新藥的投資思維，《先探週刊》特別開闢一系列的新藥個股詳細報導，讓投資人暸解這些新藥研發公司目前股價所處位置，與新藥研發的進度是如何的息息相關，如果不想將資金投注在需要長期停泊的新藥股，就要掌握、了解這些新藥研發公司所開發的新藥進度與訊息，進行波段操作也不至於錯失機會。

內容介紹：
＜第1766期（2014.2.21出刊）＞
．揭開新藥股投資密碼－追蹤進度、掌握訊息、把握機會
．F＊太景即將進入回收期－捱過最艱難階段　三顆藥將陸續產生效益

＜第1767期（2014.2.27出刊）＞
智擎胰臟癌新藥值得正面期待－三期臨床數據優於預期　策略夥伴股價已先行

＜第1768期（2014.3.7出刊）＞
安成藥進入業績檢驗期－四項新藥陸續上市　第四季力拚轉盈

＜第1769期（2014.3.14出刊）＞
浩鼎要搶首檔純抗癌新藥頭香－全球首創主體免疫療法開花結果　今年申請上櫃

＜第1770期（2014.3.21出刊）＞
基亞卡位全球第一顆肝癌新藥－競爭對手臨床試驗陸續宣告失敗 In order to allow investors to better understand the drug's investment thinking, "first exploration Week" special stocks open up a range of new drugs reported in detail, so that investors understand the drug development company stock location, with the progress of drug development is how closely related If you do not want to bet money parked in need of long-term drug stocks, it is necessary to grasp, understand the development of new drugs developed by drug companies progress and message, band operation will not have missed the opportunity.

Introduction:

. Investment password uncover drug stocks - track progress, grasp the message, the opportunity
. F * Taigen about to enter the recovery period - to survive the most difficult phase of three drugs will continue to produce benefits


Chi Qing pancreatic cancer drugs worth positive expectations - Phase III clinical data better than expected share price has first strategic partner


An inspection of medicines into the results - four new drugs onto the market in the fourth quarter, those firms from profit


Hao Ding to grab the first file of pure anti-cancer drug head incense - the world's first application for the main OTC immunotherapy fruition this year


Jiya Ka-bit world's first liver cancer drug - competitor after another failed in clinical trials